The Effect of Relugolix Combination Therapy in Black/African American Women with Uterine Fibroids
Year: 2025
Type: article
Abstract: Plain Language SummaryWhat is this summary about?This plain language summary reports results from the LIBERTY 1, LIBERTY 2, and LIBERTY Long-Term Extension clinical studies, looking specifically at outcomes in Black/African American women, as these individuals have uterine fibroids more frequently and more severe disease. These studies examined the effect of relugolix combination therapy (relugolix plus estradiol and norethindrone acetate), a medication used in women with uterine fibroids and heavy menstrual bleeding. The main aim of these studies was to investigate how well relugolix combination therapy worked in reducing menstrual blood loss in women with uterine fibroids.What were the results?In total, 70 Black/African American women received daily relugolix combination therapy for up to 1 year. Over 8 out of 10 women responded to the treatment, meaning that relugolix combination therapy decreased menstrual blood loss. In around two-thirds of women, treatment led to no menstrual periods, or little blood loss. In the blood, hemoglobin carries oxygen and anemia is associated with haemoglobin levels less than 10.5 g/dL. Around 60% of women who had anemia at the beginning of the study experienced substantial improvements in their hemoglobin (increase of more than 2 g/dL). Women also experienced improvements in their quality of life. The most common adverse events in Black/African American women were hot flushes, hypertension (which is high blood pressure), and headache. Bone loss was minimal.What do the results mean?Relugolix combination therapy is as effective in Black/African American women as the overall LIBERTY study population despite Black/African American women typically having more severe fibroid disease.How to sayUterine fibroid (YOU-Tuh-Ryne FY-Broyd)Relugolix (Reh-LU-Go-LIX)Leiomyomas (lie-o-my-O-muhs)Norethindrone acetate (NAWR-Eth-in-Drone As-Uh-Tate)This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here
Institutions: Mayo Clinic, Sumitomo Pharma Switzerland GmbH (Switzerland)
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,390
Funders: Pfizer, Sumitomo Pharma Switzerland
OpenAlex ID: W4409333404